多基因阵列表达谱检测在乳腺癌中的应用

摘要/Abstract

中图分类号:

R737.9

陈小松, 沈坤炜. 多基因阵列表达谱检测在乳腺癌中的应用[J]. 外科理论与实践, 2019, 24(05): 412-416.

[1] 陈小松, 沈坤炜. 乳腺癌多基因阵列表达谱检测与个体化治疗[J]. 中华外科杂志,2017,55(2):99-103.
[2] Perou CM, Sorlie T, Eisen MB, et al.Molecular portraits of human breast tumours[J]. Nature,2000,406(6797):747-752.
[3] Paik S, Shak S, Tang G, et al.A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med,2004,351(27):2817-2826.
[4] van de Vijver MJ, He YD, van 't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer[J]. N Engl J Med,2002,347(25):1999-2009.
[5] Dubsky P, Brase JC, Jakesz R, et al.The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients[J]. Br J Cancer,2013,109(12):2959-2964.
[6] Filipits M, Nielsen TO, Rudas M, et al.The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer[J]. Clin Cancer Res,2014,20(5):1298-1305.
[7] Paik S, Tang G, Shak S, et al.Gene expression and be-nefit of chemotherapy in women with node-negative, estro-gen receptor-positive breast cancer[J]. J Clin Oncol,2006, 24(23):3726-3734.
[8] Sparano JA, Gray RJ, Makower DF, et al.Prospective validation of a 21-gene expression assay in breast cancer[J]. N Engl J Med,2015,373(21):2005-2014.
[9] Sparano JA, Gray RJ, Makower DF, et al.Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med,2018,379(2):111-121.
[10] Sparano JA, Gray RJ, Ravdin PM, et al.Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer[J]. N Engl J Med,2019,380(25):2395-2405.
[11] Albain KS, Barlow WE, Shak S, et al.Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial[J]. Lancet Oncol,2010,11(1):55-65.
[12] Nitz U, Gluz O, Clemens M, et al.West German Study PlanB Trial: Adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of do-cetaxel and cyclophosphamide in HER2-negative early breast cancer[J]. J Clin Oncol,2019,37(10):799-808.
[13] Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med,2016,375(8):717-729.
[14] Krop I, Ismaila N, Andre F, et al.Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of Clinical Oncology Clinical Practice Guideline focused update[J]. J Clin Oncol,2017,35(24):2838-2847.
[15] Pan H, Gray R, Braybrooke J, et al.20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med,2017,377(19):1836-1846.
[16] Ma XJ, Wang Z, Ryan PD, et al.A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen[J]. Cancer Cell,2004,5(6):607-616.
[17] Sgroi DC, Sestak I, Cuzick J, et al.Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population[J]. Lancet Oncol,2013,14(11):1067-1076.
[18] Sestak I, Buus R, Cuzick J, et al.Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a rando-mized clinical trial[J]. JAMA Oncol,2018,4(4):545-553.
[19] Carey LA, Berry DA, Cirrincione CT, et al.Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase Ⅲ trial of paclitaxel plus trastuzumab with or without lapatinib[J]. J Clin Oncol,2016,34(6):542-549.
[20] Perez EA, Ballman KV, Mashadi-Hossein A, et al. Intrinsic subtype and therapeutic response among HER2-positive breaty st tumors from the NCCTG (Alliance) N9831 trial[J]. J Natl Cancer Inst,2016,28:109(2). pii: djw207.
[21] von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med,2017,377(2):122-131.
[22] Krop I, Paulson JN, Campbell C, et al.Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab(P) in HER2+ breast cancer(BC): Biomarker analysis of the APHINITY trial[J]. J Clin Oncol,2019, 37(15S):37S.
[23] Lehmann BD, Bauer JA, Chen X, et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest,2011,121(7):2750-2767.
[24] Jiang YZ, Ma D, Suo C, et al.Genomic and transcripto-mic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell,2019,35(3):428-440.

多基因阵列表达谱检测在乳腺癌中的应用

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价

[1]	曾国治, 魏子清, 岳宝, 丁云霄, 郑春元, 翟晓强.基于CNN-RNN组合模型的办公建筑能耗预测[J]. 开云网页登录学报, 2022, 56(9): 1256-1261.
[2]	李恒杰, 朱江皓, 傅晓飞, 方陈, 梁达明, 周云.基于集成学习的电动汽车充电站超短期负荷预测[J]. 开云网页登录学报, 2022, 56(8): 1004-1013.
[3]	段红燕, 唐国鑫, 盛捷, 曹孟杰, 裴磊, 田宏伟.一种新型的疲劳强度预测模型[J]. 开云网页登录学报, 2022, 56(6): 801-808.
[4]	姜俊豪, 陈刚.驾驶机器人转向操纵的动态模型预测控制方法[J]. 开云网页登录学报, 2022, 56(5): 594-603.
[5]	王子垚, 郭凤祥, 陈俐.基于外推高斯过程回归方法的发动机排放预测[J]. 开云网页登录学报, 2022, 56(5): 604-610.
[6]	张小丽　李赞　宋达疆　王业成　海涛.带蒂胸外侧动脉穿支皮瓣在保乳术后即刻乳房重建中的临床应用[J]. 组织工程与重建外科杂志, 2022, 18(5): 382-.
[7]	宋达疆　李赞　章一新.带蒂腹直肌皮瓣联合游离腹壁下动脉穿支皮瓣移植重建胸壁巨大缺损的手术策略[J]. 组织工程与重建外科杂志, 2022, 18(5): 386-.
[8]	许勇, 蔡云泽, 宋林.基于数据驱动的核电设备状态评估研究综述[J]. 开云网页登录学报, 2022, 56(3): 267-278.
[9]	姚成才　陈明　刘长春　黄传蔷　冼家仪　严国标　陈庞洲.硅凝胶乳房假体联合钛网补片在早期乳腺癌即刻乳房重建中的应用[J]. 组织工程与重建外科杂志, 2022, 18(3): 247-.
[10]	董继英　陆文婷　姚姗姗　王棽　严敏　陆茅丹　朱婕　温晓钰　姚敏.冷冻溶脂技术治疗亚洲人群皮下局部脂肪堆积的效果[J]. 组织工程与重建外科杂志, 2022, 18(3): 252-.
[11]	李瑞, 刘卓然, 严佶祺.正常血清降钙素和大肿块甲状腺髓样癌的研究进展[J]. 外科理论与实践, 2022, 27(3): 271-275.
[12]	田若岑, 张庆振, 郭云鹤, 程林.基于禁飞区规避的高超声速飞行器再入制导律设计[J]. 空天防御, 2022, 5(2): 65-74.
[13]	董继英　吴珊　王棽　严敏　米晶　林琥燕　曾颖　张逸秋　宋晨璐　裴庆　朱婕　温晓钰　陆文婷　姚敏.光电治疗对皮肤创伤性瘢痕的疗效研究[J]. 组织工程与重建外科杂志, 2022, 18(2): 133-.
[14]	姜于志　张崛　单鸿剑　高想.关节镜下改良阻挡线减张技术在大范围肩袖撕裂手术中的应用[J]. 组织工程与重建外科杂志, 2022, 18(2): 148-.
[15]	陈志鑫, 汪怡平, 杨亚锋, 苏建军, 杨斌.不同送风方式下大客车内飞沫传播特性研究[J]. 开云网页登录学报, 2022, 56(11): 1532-1540.